- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06564844
Un estudio aleatorizado de fase III del adyuvante Dato-DXd en combinación con rilvegostomig o monoterapia con rilvegostomig versus atención estándar, después de la resección completa del tumor, en participantes con NSCLC con adenocarcinoma en estadio I que tienen ctDNA positivo o tienen características patológicas de alto riesgo (TROPION-Lung12)
Un estudio global de fase III, aleatorizado, abierto, de datopotamab deruxtecan adyuvante (Dato-DXd) en combinación con rilvegostomig o rilvegostomig en monoterapia frente al tratamiento estándar, después de la resección completa del tumor, en participantes con adenocarcinoma en estadio I y cáncer de pulmón de células no pequeñas Quiénes son ctDNA positivos o tienen características patológicas de alto riesgo (TROPION-Lung12)
This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
The primary objective of the study is to assess the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig relative to SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Barretos, Brasil, 14784-057
- Research Site
-
Brasília, Brasil, 70200-730
- Research Site
-
Florianópolis, Brasil, 88034-000
- Research Site
-
São Paulo, Brasil, 01323-903
- Research Site
-
Teresina, Brasil, 64049-200
- Research Site
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canadá, B3H 2Y9
- Research Site
-
-
Ontario
-
Oshawa, Ontario, Canadá, L1G 2B9
- Research Site
-
-
Quebec
-
Montreal, Quebec, Canadá, H2X 3J4
- Research Site
-
-
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85724
- Research Site
-
-
California
-
Duarte, California, Estados Unidos, 91010
- Research Site
-
Glendale, California, Estados Unidos, 91204
- Research Site
-
Los Angeles, California, Estados Unidos, 90089
- Research Site
-
-
Colorado
-
Lone Tree, Colorado, Estados Unidos, 80124
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20007
- Research Site
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32224
- Research Site
-
St. Petersburg, Florida, Estados Unidos, 33709
- Research Site
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- Research Site
-
Evanston, Illinois, Estados Unidos, 60201
- Research Site
-
Zion, Illinois, Estados Unidos, 60099
- Research Site
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40503
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21237
- Research Site
-
-
Michigan
-
Farmington Hills, Michigan, Estados Unidos, 48334
- Research Site
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Research Site
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Research Site
-
-
Montana
-
Billings, Montana, Estados Unidos, 59102
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68130
- Research Site
-
-
New York
-
East Syracuse, New York, Estados Unidos, 13057
- Research Site
-
Mineola, New York, Estados Unidos, 11501
- Research Site
-
New York, New York, Estados Unidos, 10016
- Research Site
-
New York, New York, Estados Unidos, 10065
- Research Site
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Research Site
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Estados Unidos, 18015
- Research Site
-
Philadelphia, Pennsylvania, Estados Unidos, 19107
- Research Site
-
Pittsburgh, Pennsylvania, Estados Unidos, 15212
- Research Site
-
-
Tennessee
-
Knoxville, Tennessee, Estados Unidos, 37920
- Research Site
-
Memphis, Tennessee, Estados Unidos, 38120
- Research Site
-
Nashville, Tennessee, Estados Unidos, 37203
- Research Site
-
-
Texas
-
Austin, Texas, Estados Unidos, 78745
- Research Site
-
Dallas, Texas, Estados Unidos, 75231
- Research Site
-
Houston, Texas, Estados Unidos, 77030
- Research Site
-
San Antonio, Texas, Estados Unidos, 78217
- Research Site
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Research Site
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98104
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- Research Site
-
-
-
-
-
Hong Kong, Hong Kong, 999077
- Research Site
-
-
-
-
-
Bunkyō City, Japón, 113-8603
- Research Site
-
Chiba, Japón, 260-0877
- Research Site
-
Chūōku, Japón, 104-0045
- Research Site
-
Fukuoka, Japón, 812-8582
- Research Site
-
Hidaka-shi, Japón, 350-1298
- Research Site
-
Hiroshima, Japón, 734-8551
- Research Site
-
Hiroshima, Japón, 730-8518
- Research Site
-
Iwakuni-shi, Japón, 740-8510
- Research Site
-
Kashiwa, Japón, 277-8577
- Research Site
-
Kitaadachi-gun, Japón, 362-0806
- Research Site
-
Kobe, Japón, 650-0017
- Research Site
-
Kumamoto, Japón, 860-8556
- Research Site
-
Kōtoku, Japón, 135-8550
- Research Site
-
Nagoya, Japón, 464-8681
- Research Site
-
Niigata, Japón, 951-8566
- Research Site
-
Osakasayama-shi, Japón, 589-8511
- Research Site
-
Sapporo, Japón, 003-0804
- Research Site
-
Sendai, Japón, 980-8574
- Research Site
-
Sendai, Japón, 980-0873
- Research Site
-
Wakayama, Japón, 641-8510
- Research Site
-
Yokohama, Japón, 241-8515
- Research Site
-
-
-
-
-
Kuala Lumpur, Malasia, 59100
- Research Site
-
Kuala Lumpur, Malasia, 50586
- Research Site
-
Kuching, Malasia, 93586
- Research Site
-
-
-
-
-
Bangkok, Tailandia, 10400
- Research Site
-
Bangkoknoi, Tailandia, 10700
- Research Site
-
Banphaeo, Tailandia, 74120
- Research Site
-
Dusit, Tailandia, 10300
- Research Site
-
Hat Yai, Tailandia, 90110
- Research Site
-
Muang, Tailandia, 50200
- Research Site
-
Muang, Tailandia, 40002
- Research Site
-
Ratchathewi, Tailandia, 10400
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwán, 80756
- Research Site
-
Taipei, Taiwán, 10002
- Research Site
-
Taipei, Taiwán, 112
- Research Site
-
Taipei, Taiwán, 114
- Research Site
-
Taoyuan, Taiwán, 333
- Research Site
-
-
-
-
-
Ankara, Turquía (Türkiye), 06280
- Research Site
-
Ankara, Turquía (Türkiye), 06010
- Research Site
-
Mersin, Turquía (Türkiye), 33240
- Research Site
-
-
-
-
-
Hanoi, Vietnam, 100000
- Research Site
-
Ho Chi Minh City, Vietnam, 700000
- Research Site
-
Hà Nội, Vietnam, 100000
- Research Site
-
Vinh, Vietnam, 460000
- Research Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Histologically documented treatment-naive Stage I (T < 4 cm, AJCC 8th ed) adenocarcinoma NSCLC
- Complete surgical resection (R0) of the primary NSCLC
- Unequivocal no evidence of disease at post-surgical
- Pre-surgical ctDNA-positive result (Stage IA or IB) OR presence of at least one high-risk pathological feature (visceral pleural invasion (VPI), lymphovascular invasion (LVI), high-grade histology) (Stage IB only)
- ECOG of 0 or 1, life expectancy of > 6 months and complete recovery after surgery
- Adequate bone marrow reserve and organ function
Exclusion Criteria:
- Sensitizing EGFR mutation and/or ALK alteration
- History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
- Significant pulmonary function compromise
- History of another primary malignancy within 3 years (with exceptions)
- Any evidence of severe or uncontrolled systemic diseases, including but not limited to bleeding diseases, active infection and cardiac disease
- Active or prior documented autoimmune or inflammatory disorders (with exceptions)
- Active infection with tuberculosis, hepatitis B or C virus, hepatitis A, or known HIV infection that is not well controlled
- History of active primary immunodeficiency
- Clinically significant corneal disease
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Dato-DXd + rilvegostomig
Participants in the Dato-DXd in combination with rilvegostomig group will receive Dato-DXd and rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W). |
Datopotamab Deruxtecan IV (intravenous)
Otros nombres:
Rilvegostomig IV (intravenous)
Otros nombres:
|
|
Experimental: Rilvegostomig
Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W). |
Rilvegostomig IV (intravenous)
Otros nombres:
|
|
Comparador activo: Standard of Care (SoC)
Patients in SoC group will undergo observation or will receive Investigator's Choice of Chemotherapy (ICC). |
Carboplatin IV (intravenous), Active Comparator Cisplatin IV (intravenous), Active Comparator Etoposide IV (intravenous), Active Comparator Pemetrexed IV (intravenous), Active Comparator Vinorelbine IV (intravenous), Active Comparator UFT Oral route of administration, Active Comparator |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Disease-Free Survival (DFS) using BICR in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
Periodo de tiempo: From date of randomisation up to approximately 10 years.
|
The analysis will include all randomised participants as randomised. All events will be included, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy. The measure of interest is the HR of DFS. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
From date of randomisation up to approximately 10 years.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall Survival (OS) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
Periodo de tiempo: From date of randomisation up to approximately 10 years.
|
The analysis will include all randomised participants as randomised. All deaths will be included, regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy. The measure of interest is the HR of OS. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
From date of randomisation up to approximately 10 years.
|
|
Participant-reported physical function in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
Periodo de tiempo: Measured at weeks 12, 24 and 48.
|
The analysis will include all randomised participants as randomised. The physical function will be measured by the PROMIS SF PF 8c. Data from PROMIS SF PF 8c will capture participants' perceived ability to perform specific activities from daily life and will be scored on a 5-point rating scale. The measure of interest will be the between treatment group difference in adjusted mean in physical function scores. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
Measured at weeks 12, 24 and 48.
|
|
Participant-reported GHS/QoL in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
Periodo de tiempo: Measured at weeks 12, 24 and 48.
|
The analysis will include all randomised participants as randomised. The GHS/QoL scores will be measured by the GHS/QoL scale from EORTC IL172. The measure of interest will be the between treatment group difference in adjusted mean in GHS/QoL scores. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
Measured at weeks 12, 24 and 48.
|
|
Pharmacokinetics (PK)
Periodo de tiempo: Up to 30 or 90 days post-last dose of study intervention.
|
Concentration of Dato-DXd, total anti-TROP2 antibody, and MAAA-1181a (payload deruxtecan) in plasma or serum. |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Pharmacokinetics (PK)
Periodo de tiempo: Up to 30 or 90 days post-last dose of study intervention.
|
Concentration of rilvegostomig in plasma or serum. |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Pharmacokinetics (PK)
Periodo de tiempo: Up to 30 or 90 days post-last dose of study intervention.
|
PK parameters (peak and through concentrations). |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Immunogenicity
Periodo de tiempo: Up to 30 or 90 days post-last dose of study intervention.
|
Presence of ADAs for Dato-DXd and rilvegostomig (confirmatory results: titres and neutralising antibodies for confirmed positive samples). |
Up to 30 or 90 days post-last dose of study intervention.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: David Jones, MD, Memorial Sloan Kettering Cancer Center, New York, United States of America
- Investigador principal: Enriqueta Felip, MD, Vall d'Hebron Hospital, Barcelona, Spain
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por sitio
- Neoplasias
- Enfermedades de las vías respiratorias
- Neoplasias por tipo histológico
- Enfermedades pulmonares
- Neoplasias Glandulares y Epiteliales
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Neoplasias Pulmonares
- Carcinoma
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Carcinoma de pulmón de células no pequeñas
- Adenocarcinoma
- Aminoácidos, péptidos y proteínas
- Químicos orgánicos
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Hidrocarburos
- Hidrocarburos, cíclico
- Carbohidratos
- Alcaloides
- Podoflotoxina
- Tetrahidronaftalenos
- Naftalenos
- Hidrocarburos aromáticos policíclicos
- Hidrocarburos, aromáticos
- Compuestos policíclicos
- Glucósidos
- Glucósidos
- Indoles
- Químicos inorgánicos
- Compuestos de cloro
- Compuestos de nitrógeno
- Complejos de coordinación
- Guanina
- Hipoxantino
- Purinones
- Purinas
- Glutamatos
- Aminoácidos, ácido
- Aminoácidos
- Aminoácidos, dicarboxílico
- Alcaloides de Vinca
- Alcaloides de triptamina de secologanina
- Alcaloides de indol
- Indolizidinas
- Indolizinas
- Compuestos de platino
- Vinorelbina
- Pemetrexed
- Etopósido
- Carboplatino
- Cisplatino
Otros números de identificación del estudio
- D926TC00001
- 2024-512195-35-00 (Identificador de registro: CTIS)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Marco de tiempo para compartir IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Criterios de acceso compartido de IPD
When a request has been approved, AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool.
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .